The US Food and Drug Administration (FDA) has approved Idvynso, a groundbreaking two-drug single-tablet regimen combining 100 mg doravirine and 0.25 mg islatravir, for treating HIV-1 infection in adults. As reported by PharmaBiz.com, the approval marks a significant advance in HIV therapy, offering patients and clinicians an innovative alternative to currently available treatment options. Idvynso will be available in pharmacies starting May 11, 2026.
A Novel Treatment Approach
Idvynso represents a unique combination as the only two-drug, non-INSTI (integrase strand transfer inhibitor), tenofovir-free regimen available. It combines islatravir, a next-generation nucleoside analog reverse transcriptase inhibitor (NRTI) with multiple mechanisms of action, with doravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has an established efficacy and safety profile. This dual-action approach works through inhibition of reverse transcriptase translocation and induction of structural changes in viral DNA, effectively blocking HIV-1 replication through complementary mechanisms.
Who Can Take It
Idvynso is designed for virologically suppressed adults, those with HIV-1 RNA levels below 50 copies per mL who are stably controlled on their current antiretroviral therapy. Importantly, it’s intended to replace existing regimens in patients with no history of virologic treatment failure and no known resistance substitutions to doravirine. However, Idvynso is contraindicated with strong CYP3A enzyme inducers and certain other antiretrovirals like lamivudine or emtricitabine.
Strong Clinical Evidence
Two randomized, active-controlled trials involving 708 total participants demonstrated Idvynso’s effectiveness. Trial 052 compared Idvynso to Biktarvy in 513 participants, while Trial 051 tested Idvynso against various baseline antiretroviral regimens in 551 participants.
At Week 48, Idvynso proved non-inferior to comparison regimens. In Trial 052, 99% of Idvynso recipients maintained viral suppression compared to 94% on Biktarvy. In Trial 051, 96% on Idvynso maintained suppression versus 92% on baseline therapy. Notably, treatment outcomes remained consistent across subgroups by age, sex, and race, with older participants (65+) showing no safety or effectiveness differences from younger patients.
Safety Profile
Idvynso demonstrated a generally favorable safety profile comparable to standard treatments. Discontinuations due to adverse events were minimal, 3% in the Idvynso group versus 2% for Biktarvy in Trial 052, and 0.5% versus 2% in Trial 051. The most common adverse reactions included diarrhea, dizziness, fatigue, and headache, occurring at rates of 1-3% across trials. Participants taking Idvynso showed minimal weight changes, averaging -0.03 kg in one trial.
Clinical Significance
Dr. Eliav Barr, Merck’s chief medical officer, emphasized that Idvynso addresses evolving health needs in aging HIV populations managing multiple chronic conditions simultaneously. This approval expands therapeutic diversity and provides clinicians with a genuinely new treatment option beyond existing regimens.
Merck’s Commitment
With 40 years of HIV research and discovery, Merck continues pioneering breakthrough treatments across multiple drug classes. The company is also advancing islatravir in multiple clinical trials, including Phase 3 studies for once-weekly HIV treatment combinations and collaborating on pre-exposure prophylaxis (PrEP) development.
Merck offers comprehensive patient support programs, including insurance coverage assistance and co-pay support for eligible individuals through The Merck Access Program, ensuring access barriers don’t prevent treatment initiation.
